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Abstract Recent progress in molecular engineering has
contributed to the great progress of medicine. However,
there are still difficult problems constituting a challenge for
molecular biology and biotechnology, e.g. new generation
of anticancer agents, alternative biosensors or vaccines. As
a biotechnological tool, bacteriophages (phages) offer a
promising alternative to traditional approaches. They can
be applied as anticancer agents, novel platforms in vaccine
design, or as target carriers in drug discovery. Phages also
offer solutions for modern cell imaging, biosensor con-
struction or food pathogen detection. Here we present a
review of bacteriophage research as a dynamically devel-
oping field with promising prospects for further
development of medicine and biotechnology.
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Introduction
Recent progress in molecular engineering has contributed
to the great progress of medicine. Biopharmaceutics such
as hormones, interferons, interleukins, hematopoietic
growth factors or therapeutic enzymes constitute a new
class of drugs. They have found application in various
diseases including anemia, leukemia, multiple sclerosis,
diabetes and many others. The beginning of modern bio-
technology dates back to 1982, when recombinant human
insulin for the first time was introduced for treatment of
diabetes. Later that success was continued with production
of human growth hormone as the first fusion protein in
1985. Among promising molecular tools in biotechnology,
molecular biology or medicine phages can be used. Phages
have induced progress in such biotechnological branches
as: biosensors, drug-carrying particles, cancer cell imaging
agents, investigation of phage proteins’ structure and
function, epitope mapping, studies of protein–protein
interactions, determination of inhibitors’ and enzymes’
specificity, screening for receptor agonists and antagonists
and finally for vaccine design, and anti-cancer research.
These may contribute to the development of alternative
methods in medicine, for examples in still serious medical
problems like high risk of cancer or AIDS.
Phage Display
Probably the first idea of phage application as a modern
biotechnology tool was phage display. Phage display is a
molecular technique that allows expression of exogenous
proteins on a bacteriophage surface. The first report
describing display of a foreign polypeptide on the surface of
a bacteriophage particle comes from 1985 (Smith 1985).
George P. Smith introduced a fragment of the EcoRI re-
strictase coding sequence into the middle section of gene 3
of the non-lytic filamentous phage f1. The new fusion
protein P3-EcoRI did not destroy phage infectivity and the
presented EcoRI retained antigenic properties of its native
form. Filamentous phages that do not lyse infected bacteria
during their propagation cycle have been most commonly
used as phage display platforms (Huang et al. 2012a).
Infection caused by these phages does not cause cell lysis,
only ‘‘constant production’’, which results in twice as slow
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growth of bacteria (Czaplicki 2005). However, T4 and T7
phages that represent lytic Caudovirales have also been
used for phage display (Efimov et al. 1995). The lytic cycle
results in the destruction of the infected cell after the phage
penetrates into bacteria; the replication and expression of
the bacterial genetic material changes in favor of the phage.
After the assembly and maturation of virions, the cell wall is
destroyed and viruses can infect other cells (Karam 1994).
Filamentous phage strains such as M13, fd or f1 (Smith
and Petrenko 1997) are characterized by a flexible rod
shape with a circular ssDNA genome. They infect Esche-
richia coli via the F pilus. The M13 capsid is built by 2,700
copies of major coat protein p8 and is capped by p3 (5
copies), p6 (5 copies), p7 (5 copies), and p9 (5 copies). All
these coat proteins can be used as fusion targets for display,
but p3 and p8 proteins are used most widely. Protein p8 is
limited to displaying short peptide sequences, while p3
allows display of larger insertions (Pande et al. 2010).
The most popular way for expression of a foreign peptide
or protein on the bacteriophage surface is the fusion pro-
posed by Smith (1985). A gene encoding the foreign protein
is fused to one of the M13-related viral coat protein genes.
Filamentous phage expression is ideal for oligopeptides and
small proteins (Bratkovicˇ 2010); in the case of bigger pro-
teins, this platform is insufficient. This problem has been
solved by the introduction of phagemids as special helping
display vectors (Bass et al. 1990). A phagemid is a plasmid
with phage origin of replication and packing signal which
can express a fusion protein but does not encode any viral
structural or replication proteins. Fusion proteins are carried
by phagemids while the majority of the genes required for
the formation of phage particles are carried by helper pha-
ges that are co-infected together with phagemids into host
bacteria (Sidhu 2001). Co-infection of the bacterial host cell
by a phagemid and a phage produces hybrid virions dis-
playing only a few copies of the fusion coat protein
additionally to the majority of wild-type structural coat
proteins (Pande et al. 2010). This system is called a
‘‘hybrid-phage system’’, and has been created by Smith
(Smith’s classification); this system is based on the
arrangement of the coat proteins (McConnell et al. 1994).
The authors introduced the terms 3, 33 or 3 ? 3 (for p3-
based display), 6, 66, or 6 ? 6 (for p6-based display), and 8,
88, or 8 ? 8 (for p8-based display) to differentiate possible
protein arrangements (Smith and Petrenko 1997). Type 3, 6
and 8 are the simplest cases. A foreign protein is displayed
on each copy of a phage protein in the capsid. Types 3 ? 3,
6 ? 6, and 8 ? 8 of the system engage a combination of the
phage and the phagemid, allowing combination of fusion
proteins and wild proteins in the same capsid. Types 33, 66,
88 also allow one to combine fusion proteins and wild
proteins in the same capsid, but they are expressed from the
same phage genome (Bratkovicˇ 2010).
Later, in a relatively short time, phage display was
developed into a wide range of variations, employing dif-
ferentiated phage strains and several technological
approaches. Now, the multiplicity of phage display varia-
tions can by classified according to diverse aspects of these
techniques (Table 1).
Phage capsid in the phage display can contain only
fusion protein or both fusion and native wild-type proteins.
Phage display with fusion proteins can be grouped into two
types: permanent fusion of phage and foreign genes in
phage genome, which can be classified as type 3, 6 or 8
according to Smith’s ordination (description above). It can
also be done by deletion of a non-essential phage coat
protein followed by the introduction of a selected fusion to
the phage capsid. This second type is based primarily on
the T4 bacteriophage. The phage T4 capsid is built with
two essential proteins, gp23* and gp24*, and two decora-
tive proteins: Hoc (highly antigenic outer capsid protein)
and Soc (small outer capsid protein). The in vivo display
system allows for target fusion, which will be displayed on
the phage surface to the capsid protein. Capsid proteins
fused to foreign proteins or peptides are overexpressed in a
bacterial system such as the E. coli system. During
assembly, these fusions are incorporated into the phage
capsid by simply mixing. Protein (Hoc-target or Soc-target)
is built into hoc- or soc- phage by simply mixing. The
phage strains used in the experiments with supplementary
expression vectors had a deletion or a non-sense mutation
in the gene, and thus no native gene products have been
incorporated into its head during phage assembly. Since
Hoc and Soc are not essential head proteins, these defects
do not affect phage viability (Jiang et al. 1997; Os´lizło
et al. 2011; Ren et al. 1996; Ren and Black 1998). This
system was used, e.g. to display full-length antigens from
human immunodeficiency virus (HIV) (Li et al. 2007;
Shivachandra et al. 2006). In vivo systems have been used
on other phages such as k or T7 phage (Castagnoli et al.
2001; Maruyama et al. 1994; Mikawa et al. 1996). One of
the limitations of in vivo display is the fact that no control
can be exerted on intracellular expression structure and
assembly on foreign proteins. This problem is solved by the
use of in vitro phage display. This system differs from that
extended in vivo because of incorporation of target proteins
to the capsid outer bacterial cell on mature bacteriophage
particles. In vitro phage display has been reported in the
first presentation of a 710 kDa anthrax toxin on bacterio-
phage T4 (Li et al. 2006).
Phage display with both fusion and native proteins, as
its name suggests, engages two types of proteins at the
same time: fusion proteins and wild-type protein. Fusion
protein is made by fusion of foreign amino acid sequence
to the endogenous amino acids of the coat protein. Fusion
protein can be expressed from the plasmid (competitive
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phage display), phagemid (type 3 ? 3) or phage genome
(type 33).
Phage Display Libraries
The most common applications of phage display constructs
are random peptide libraries. A phage library is a collection
of phages carrying on their surface foreign proteins or
peptides encoded by DNA inserted into the phage genome
(e.g. type 3 phage display) (Smith 1993). One of the most
important functions of phage libraries is to deliver a
diversified pool of elements. Each phage displays on its
surface a single type of protein or peptide, but the whole
library has a large number of viruses with many different
proteins in total. Each viral vector is capable of infection,
and therefore each phage selected from the phage library
with the respective peptide can be separately replicated in
bacteria. The method for the production of peptide libraries
is based on Zoller and Smiths’s procedure (Zoller and
Smith 1982, 1983); it allows a foreign nucleotide sequence
to be introduced into the M13 vector, which causes for-
mation of mutant clones capable of displaying a respective
peptide. This method can be used to construct libraries of
the size ranging 109–1011 (Huang et al. 2012a). Scholle
et al. (2005) created libraries with 100 % recombinant
phages by the use of negative selection of amber stop
codon at the 50 end of the gene p3 in the filamentous phage.
One of the most popular applications of phage display
libraries is selection for affinity domains of antibodies. In
1990, McCafferty and colleagues (1990) for the first time
displayed complete V variable domains of antibodies on
the surface of a filamentous phage. Thus, they initiated a
new way of making antibodies demonstrated using poly-
merase chain reaction (PCR) reaction. Phage display
antibody libraries are a combination of heavy-chain vari-
able domain (VH) with light-chain variable domain (VL)
which are presented on a phage surface (Pini and Bracci
2000). These two domains together form the variable
domain (V domain) which is responsible for antigen
binding and unique specificity. The traditional molecular
method for producing antibody fragments uses the phage-
mid vector including the V domain from lymphocytes
which is amplified by PCR (Table 2).
There are two categories of antibody libraries: post-
immunization libraries and single-pot libraries. The first
type contains the immunoglobulin G (IgG) sequence
derived from the spleen B cells of immunized animals. V
genes are isolated and assembled into functional antibody
fragment (mostly scFv or Fab) and inserted into phage
library vectors. Post-immunization libraries have high
affinity to an antigen; it is however necessary to construct a
new library for every antigen. Single-pot libraries use B
cells from unimmunized donors. Two types of single-pot
library have been developed: naı¨ve and synthetic. Naı¨ve
libraries are constructed using V genes sequences that have
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undergone some natural rearrangement, for example those
derived from IgM mRNA. Synthetic libraries are built
in vitro on rearranged antibody gene segments with some
additional sequences; therefore, good knowledge of the
complementary determining region (CDR) sequences,
which are critical for antigen binding, is necessary (Smith
et al. 2005; Willats 2002).
Phage Display Applications
Phage display can be used in a variety of applications as
presented in exemplary use in experimental animal or
in vivo models, e.g. for epitope mapping (Fack et al. 1997),
studies of protein–protein interactions (Sidhu et al. 2013),
to determine specificity of inhibitors and enzymes (Diamod
2007; Hawinkels et al. 2007), in screening for receptor
agonists and antagonists (Lee et al. 2001), or in vaccine
design (De Berardinis and Haigwood 2004; Ren et al.
1996; Ren and Black 1998; Sathaliyawala et al. 2006). Due
to the wide range of possibilities offered by phage display,
this method is postulated as a tool for looking of solution in
many medical problems.
The most popular one is screening for anticancer pep-
tides or proteins. There are many publications describing
peptides’ selection by phage display. These peptides are
able to influence angiogenesis and tumor cell growth
(Cieslewicz et al. 2013; Lu et al. 2012; Mai et al. 2009).
One of the best characterized and important factors causing
angiogenesis is vascular endothelial growth factor (VEGF);
moreover, this factor is responsible for tumor growth
stimulation. It is the key mediator of angiogenesis (the
formation of new blood vessels), and binds two types of
VEGF receptors (VEGFR1 and VEGFR2) (Carmeliet
2005). It has been demonstrated that VEGF is responsible
for stimulation and cancer metastasis, and therefore is a
frequent therapeutic target. The VEGF family and its
receptor system has been shown to be the fundamental
regulator in the cell signaling of angiogenesis (Lu et al.
2003). The phage display method allows one to select
peptides that are capable of inhibition of tumor growth
(Borysowski and Go´rski 2004). From a large human naı¨ve
antibody library four fully human anti-KDR (KDR, kinase
insert domain-containing receptor or VEGFR2) antibodies
were identified and it was demonstrated that these anti-
bodies were able to block KDR/VEGF interaction and
neutralize VEGF-induced angiogenic activity (Lu et al.
2002). Other studies described 90Y-labeled nanoparticles
targeted to the vasculature with anti-VEGFR antibodies for
anti-tumor therapy (Li et al. 2004).
Fibroblast growth factor 8b (FGF8b) is the major iso-
form of FGF8 expressed in prostate cancer and it correlates
with the stage and grade of the disease. Using the phage
display method 12 specific FGF8b-binding phage clones
were constructed and isolated by screening a phage display
heptapeptide library with FGF8b, which was named as P12.
Studies suggested that P12 may have a greater potential to
interrupt FGF8b binding to receptors than others, which
were identified by phage display libraries. Functional
analysis indicated that synthetic P12 peptides mediate
significant inhibition of FGF8b-induced cell proliferation
and blockade of the activation of Erk1/2 and Akt cascades
in both prostate cancer cells and vascular endothelial cells
(Wang et al. 2013).
Cysteine-rich protein 61 (CCN1/Cyr61) has been used
as an important mediator in proliferation and metastasis of
breast cancer; blockage of Cyr61 might be a potent target
for breast cancer treatment. Using the phage display system
developed antibody denoted as 093G9, an inhibitory effect
on breast human cell line proliferation and migration was
induced. Additionally, 093G9 also showed significant
efficacy on suppressing primary tumor growth and spon-
taneous lymph node metastasis in vivo in a mouse model
(Lin et al. 2012).
High exposure of selected antigens on the phage display
platform and the relative ease of their production make
phage display a promising tool for constructing vaccines.
This includes the challenge of developing an effective
vaccine for HIV (Burton et al. 2004; Esparza 2005). Bac-
teriophage T4 has been proposed as a recombinant
platform that allows construction of multicomponent vac-
cine boosting humoral and cellular responses (Ren et al.
1996; Ren and Black 1998; Sathaliyawala et al. 2006). The
head of T4 bacteriophage is an icosahedron with one portal
Table 2 Types of antibody phage display
Types of antibody phage display
Immunization of animals with
target molecule
Yes (post-immunization libraries) No (single-pot libraries)
V-gene construction In vivo
IgG mRNA from B cells
In vivo (naı¨ve libraries)
IgM mRNA from B cells
In vitro (semi-synthetic libraries)
Random sequence of antibody coding
genes mRNA from pre-B cells
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vertex (120 9 86 nm) to which the phage tail is attached
(Fokine et al. 2004; Rao and Black 2010). The icosahedral
caps are formed by hexamers of gp23* and pentamers of
gp24*, which are essential proteins. Hoc and Soc are two
nonessential proteins (Leiman et al. 2003). The nonessen-
tial proteins have a number of features that recommend
them as alternative vehicles for protein display. Ren fused
the V3 loop domain of gp120 (HIV-1 envelope glycopro-
tein) to Soc protein. Soc-V3 fusion was expressed in the
E. coli system, and then bound in vitro to the phage. Soc-
V3 displaying phage were highly antigenic in mice and
produced antibodies reactive with native gp120 (Ren et al.
1996). Further, a Hoc-based in vivo assembly system
allowed display of HIV antigens p24-gag, Nef and gp41
C-peptide trimer, which represent differentiated structures
and biological function. P24 displayed as a Hoc-fusion was
highly immunogenic in mice in the absence of any external
adjuvant, eliciting strong p24-specific antibodies, as well as
Th1 and Th2 cellular responses with a bias toward the Th2
response. The phage T4 system, which was used in these
experiments, increases the range of immune responses;
therefore, it was proposed for HIV vaccine development
(Ren et al. 1996; Ren and Black 1998; Sathaliyawala et al.
2006).
Phage display can also be used to design new antibac-
terial peptides. This may be useful when phages specific to
difficult pathogens are not available, which has been shown
in the case of phage specificity to Staphylococcus aureus
and Helicobacter pylori. S. aureus cause many diseases by
producing toxins, such as pneumonia, endocarditis, men-
ingitis, septicemia, and toxic shock syndrome (Lowy
1998). A large percentage of S. aureus infections are
caused by MRSA (Methicillin-resistant S. aureus). Devel-
opment of resistance to available antibiotics has become a
serious problem in treatment of S. aureus infections (Lowy
2003). There is therefore an imperative need to find new
types of antibacterial agents. H. pylori is a Gram-negative
bacterium which produces the virulence factor urease. This
allows survival of the bacteria in the acidic environment of
the stomach. H. pylori causes many serious diseases
including duodenal ulcers and stomach cancer. Antibiotic
therapy has significant limitations, such as the high cost
and the emergence of antibiotic-resistant strains, generating
the need for new ways of treatment. For selection of new
specific peptides capable of binding difficult bacterial
pathogens, phage display library screening can be utilized
(Ardekani et al. 2013).
Phage display libraries are used for identification of
specific peptides and antibodies against pathogen targets.
Synthesis of virulence factors produced by S. aureus is
regulated by a quorum-sensing mechanism. S. aureus
secretes a protein termed RNAIII activating protein (RAP)
which autoinduces toxin. Young and colleagues showed
that mice which have been vaccinated with selected RAP
were protected from S. aureus infection, which suggested
that RAP is a useful target for selecting potential thera-
peutic molecules to inhibit this pathogen (Yang et al.
2003). Peptides recognizing staphylococcal enterotoxin B
(SEB) selected from the M13 phage library were applied to
attenuate this bacterium. SEB is a pyrogenic toxin
responsible for staphylococcal food poisoning in humans
and has been an attractive choice as a biological aerosol
weapon due to its inherent stability and high intoxication
effect (Ler et al. 2006). Three peptides of high affinity to
SEB (WRPLTPESPPA, MNLHDYHRLFWY,
QHPQINQTLYRM) were highly active against Staphylo-
coccus (Soykut et al. 2008).
Phage display technology was used for identification of
peptides able to bind specifically and to inhibit H. pylori
urease such as 24-mer TFLPQPRCSALLRYLSEDG-
VIVPS and 6-mer YDFYWW that can inhibit the activity
of urease purified from H. pylori (Houimel et al. 1999). In
another approach, an antibody display was developed for a
single-variable domain of heavy chain antibody against
recombinant UreC. The isolated UreC nanobody can spe-
cifically detect and bind to UreC and inhibit urease activity
(nanobodies are isolated variable domains of heavy chain
antibodies). This nanobody could be a novel class of
treatment measure against H. pylori infection (Ardekani
et al. 2013). The identification of inhibitory peptides and
nanobodies specific for H. pylori urease may open a new
approach for the development of therapeutic drugs.
Recently, phage display was applied in purification of
bacteriophages. New methods combining phage display
and chromatography give good results in separating T4
bacteriophages from bacterial proteins, DNA, lipopoly-
saccharides and even from other phages (Ceglarek et al.
2013; Os´lizło et al. 2011). It is a very useful technique for
purification of phages compared to other methods, e.g.
gradient centrifugation in cesium or saccharose, which are
more time-consuming operations. Moreover, because of
this method phages are highly purified. There are two
methods, one based on competitive phage display, in which
bacterial cells produce both wild-type proteins (expressed
from the phage genome) and the protein fusions with
affinity tags (expressed from expression vectors). These
tags are glutathione S-transferase (GST) or six histidine
(His-tag); phage proteins fused to the tags are incorporated
into the phage capsid during assembly.
Random Mutagenesis of Bacteriophages
Random mutagenesis is the process of introducing changes
inside bacteriophage DNA without pre-designing these
changes. Random mutagenesis can be spontaneous or
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induced. Spontaneous mutagenesis results from errors in
DNA replication; this kind of mutant occurs frequently in
the environment. Random mutations can also be inducted
by many physical or chemical factors. Physical factors
causing changes in DNA are ionization, UV radiation and
temperature. Acridine dyes, nitrogenous base analogs,
nitric acid, some hydrocarbons and others are chemical
inductors of mutations. Mutations induced by physical or
chemical mutagens are a very popular approach in research
methodologies. They make it possible to examine functions
of genes based on changes in phenotype characteristics.
At the molecular level, random mutagenesis techniques
base on typical kinds of point mutations, including transi-
tions, transversions, frameshift mutations and deletions.
The principal strategy of random mutagenesis is formation
of random mutations by chemical or physical mutagens, and
selection of mutants with altered properties. This technique
does not require detailed knowledge of the phage. The main
point is the modification of phage phenotype and the
assumption that mutation in the genome is responsible for
the new virus properties. Random mutagenesis is more of a
random modification at the molecular level than genetic
engineering; however, when well planned, it allows for the
selection of a phage even with very sophisticated properties.
A good example is provided by the studies of Merril et al.
(1996). They isolated k and P22 phage mutants which can
circulate longer in mice in comparison to wild-type phages,
which was related to one point mutation located in a major
head protein coding gene. Another example of the appli-
cation of random mutagenesis is identification and selection
of their most able T4 lysozyme. Two variants were found,
which exhibited increased reversible melting temperatures
with respect to the wild-type protein. The results also
illustrate the power of random mutagenesis in obtaining
variants with a desired phenotype (Pjura and Matthews
1993). UV irradiation is one of the most popular physically
induced methods of mutagenesis. T4 phage can be inacti-
vated by UV light at a wavelength of 253.7 ml. Mutation in
a single gene m that controls the repair process by photo-
reaction causes increased UV sensitivity in T4 phage (Harm
1963). Hall and colleagues have applied bacteriophages in
studies of coevolutionary dynamism of phages and their
hosts. These authors examined interaction between bacteria
and a phage by the use of a parasitic phage with random
mutations in its tail fiber. They demonstrated that random
mutations could be a very useful tool for investigation of a
phage influence on the genetic divergence of bacterial hosts.
One of the most interesting conclusions was that bacterio-
phages were more likely to emerge through long-term
coevolution with their hosts than through spontaneous
adaption to a single novel host (Hall et al. 2011a, b).
Site-directed mutagenesis is a phage modification tech-
nique leading to introduction of designed changes into a
specific site in the genome. It involves specially designed
synthetic oligonucleotides, i.e. primers for PCR. Mutagenic
primers are complementary to the part of the engineered
DNA template, but they also contain an internal mismatch
which codes for a designed change of the selected genes.
Specified changes in nucleotide sequences of a gene lead to
modification of amino acid sequences in the protein often
enabling introduction or removal of a considerable number
of amino acids.
Thus site-directed mutagenesis allows studies of
molecular determinants of protein structure and function
(Switala-Jelen et al. 2002).
A molecular tool that allows for the introduction of site-
directed mutagenesis is the bacteriophage insertion-sub-
stitution (I/S) vector system. This system was first derived
by Selick et al. (1988) for T4 bacteriophage. This method
enables the transmissions of in vitro-generated mutations
from a plasmid into the phage gene. The mutation insert is
first constructed as a cloned insert within the I/S plasmid.
Bacteria containing this plasmid are then infected with
bacteriophage that carries amber mutations in selected
genes. The plasmid integrates the mutation-containing
sequence into the phage genome by homologous recom-
bination. Integrant phage mutants are selected by
comparison of their growth on the amber-suppressing and
non-suppressing bacterial strains.
This technique allows for introduction of almost any
changes in the genes. Therefore, site-directed mutagenesis
is a very popular technique that has been used for studying
gene function and protein structure/function. Site-directed
mutagenesis has helped in understanding the function and
structures of some important gene products such as gene 32
from T4 phage (Shamoo et al. 1989) or the role of D-loop
using ATP binding cassette proteins from T4 phage and
gp47 (De la Rosa and Nelson 2011). Moreover, it is widely
used for engineering disulfide bonds in the case of T4
lysozyme and improves its stability (Perry and Wetzel
1984).
Site-directed mutagenesis is in fact a molecular tool for
constructing recombinant phage libraries which display
foreign peptides on surfaces (Huang et al. 2012b). It is used
for constructing libraries of protein variants in M13 bac-
teriophage (Fellouse et al. 2007; Huang et al. 2012b). This
powerful technique allows us to obtain phage display
libraries that comprise a vast number of mutants, as it has
been observed that the size of a phage library is closely
correlated with the affinity of the isolated mutants (Ling
2003).
Site-directed mutagenesis was recently studied by Yoi-
chi et al. (2005). They modified phage lytic spectrum by
changes in tail fiber protein gp38 of T2 bacteriophage. In
that research, homologous recombination between T2
phage genome and a plasmid encoding the region around
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genes 37-38 from PP01 phage was used. Authors obtained
recombinant T2ppD1phage derived from T2 which carried
gp37 and gp38 from PP01 phage. Insertion of foreign gp37
and gp38 into T2 phage conferred infectivity of the het-
erogeneous host E. coli O157:H7 which was not sensitive
to the wild-type of T2. E. coli K12 strains which was the
original host of T2, could not be infected by recombinant
T2ppD1 phage. Site-directed mutagenesis could be
employed for customizing of phage host range according to
specific needs. This may have practical significance for
phage therapy and identification of bacteria (Yoichi et al.
2005).
Bacteriophage recombineering of electroporated DNA
(BRED) is the most powerful technique allowing for phage
mutant creation. It has been mainly applied on temperate
phages but developments for lytic phages are also emerg-
ing. This approach was first used in mycobacteriophages.
BRED can be used for the construction of unmarked
detection in essential as well as nonessential genes. It can
take advantage of creation in-frame internal deletions,
point mutations, nonsense mutations and additions of gene
tags. BRED strategy allows for co-electroporation of phage
DNA temple and targeting substrate to recombineering
Mycobacterium smegmatis cells. This strategy offers a very
high effectiveness of mutant construction; as reported by
the authors more than 10 % of finally recovered plaques
contained the desired mutant (Marinelli et al. 2008; van
Kessel and Hatfull 2008). Recombinieering phages tech-
nique has been applied also for k phage (Oppenheim et al.
2004). There are many potential possibilities offered by
BRED technology, mostly for investigations of bacterio-
phage genetics. Phage genomes can by modified with genes
of unknown function which may allow for the function
identification.
New concept for using phages as detection tools are
fluorescent and luminescent-labeled phages. Bacterial
lucyferase gene (lux) was transferred to a phage genome
for first time by Ulitzur and Kuhn (1987). The gene was
cloned into the bacteriophage k genome. Reporter phages
with lucyferase gene were demonstrated as creative tools
for rapid detection of bacterial host cells following phage
infection. The minimum number of cells which can be
detected did not exceed ten for E. coli (Ulitzur and Kuhn
1987), one hundred for Salmonella typhimurium (Stewart
et al. 1989), or ten for enterobacterial cells (Kodicara et al.
1991). Loessner et al. (1996) developed new recombinant
phage against Listeria: A511::luxAB by introduction of the
luxAB genes into the gene coding major capsid phage
protein. After infection they observed a high level of
luciferase expression in bacterial cells (Loessner et al.
1996). These bacteria are food borne pathogens which
gives a high practical potential to this new method of
identification.
Other approach that employs light for phage detection is
that based on green fluorescent protein (GFP) introduced to
the phage capsid. This technique combines mutagenesis
and phage display method. Small outer capsid (SOC)
protein of PP01 phage was used as a platform to present a
marker protein GFP. Fusion of GFP to SOC did not change
host range of the phage, interestingly, binding of the
recombinant phage to bacterial cells enhanced. Adsorption
of the GFP-labeled PP01phages to the E. coli cell surface
enabled visualization of cells under a fluorescence micro-
scope. The fluorescence of GFP within infected bacteria
enables highly sensitive detection (Oda et al. 2004).
Kaz´mierczak et al. (2014) proposed T4 phage as a new tool
for molecular imaging of bacteriophages in living systems.
They used T4 phage mutant HAP (T4 without decorative
Hoc protein). GFP was fused to the N-terminus of Hoc by
in vivo phage display. Fluorescent phages were positively
assessed as regards their applicability for detection inside
living mammalian cells (by phagocytosis) and tissues (fil-
tering and retention by lymph nodes and spleen)
(Kaz´mierczak et al. 2014).
Another application of site-directed mutagenesis is
using this method for affinity maturation of antibodies or
for epitope mapping. These approaches usually combine
construction of phage-displayed antibody libraries with
mutagenesis. Parent antibody sequence is subjected to
mutagenesis which is followed by optimized selection of
affinity-improved variants. These variants are selected
against a relevant target. Combination of phage display and
site-directed mutagenesis is usually applied to understand
the structure, function and interactions between antibodies
and antigens (Infante et al. 2014; Lamdan et al. 2013).
Chemical Modification of Bacteriophage Particles
Most chemical modifications of bacteriophages are based
on conjugation of some prosthetic groups to the phage
surface. Various chemical compounds can be attached to
the surface protein in a specific reaction at the appropriate
temperature, incubation time and favorable pH. Conditions
of the incubation reactions are relatively non-aggressive, so
the phage does not lose its biological properties. By this
reaction, such reactive groups can be attached as amino
groups of lysine residues, carboxylic acid groups of
aspartic acid, glutamic acid residues, the phenol group of
tyrosine residues, some ester bond linkers and a chemical
monolayer. To these linkers can be further attached to folic
acid, some fluorescent markers, or even various antibiotics.
Moreover, chemical conjugations allow one to attach
polyethylene glycol particles directly to a phage.
Li and colleagues’ data showed a potential application
of the M13 phage in cell imaging. For dual modification of
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M13 they chose the most reactive group, tyrosine, as the
site where fluorescent dye and folic acid were attached.
Folic acid is one of the most common ligands for cancer
cell targeting. Dual-modified M13 showed very good
binding to HeLa contaminant of KB cells, thus demon-
strating the potential of chemically modified M13 in bio-
imaging and drug delivery (Li et al. 2010).
Chemical modification of phages allows them to be used
in targeted drug therapy. A very interesting research paper
by Yacoby et al. (2007) presented bacteriophage M13 as a
platform of targeted drug carriers for the eradication of
pathogenic bacteria.
The same phage was used for the conjugation of anti-
biotic and IgG antibodies. IgG attached on each P3 protein
allowed for recognition of the target and P8 coat protein
with a conjugated drug designed to kill bacteria. A sche-
matic representation of antibacterial-targeted drug carrying
bacteriophages can be summarized in three steps: (1) pre-
paring a pro-drug; (2) conjugating the pro-drug to the
phage; (3) drug-carrying phage binding to the target bac-
teria and drug release.
This research offered a new approach to selective drugs
of a targeted specificity by the attached elements, which
may allow the reintroduction of nonspecific drugs that have
thus far been excluded from antibacterial use because of
toxicity or low selectivity. Drug-currying phage has high
selectivity against bacteria; in general use, it may help to
combat emerging bacterial antibiotic resistance (Yacoby
et al. 2006).
PEGylation is a very noteworthy type of chemical
modification. It allows for phage structural protein conju-
gation with polyethylene glycol (PEG). After PEGylation
bacteriophages do not change their specificity to bacteria.
In vivo and in vitro experiments with mice showed that
PEGylation of bacteriophages is efficient to delay virus
clearance and achieve longer circulation in non-immunized
mice. Additionally, PEGylation can reduce the cellular
immune response such as antigen-specific T cell prolifer-
ation (Kim et al. 2008). This chemical modification of
bacteriophages may have great significance for phage
therapy against antibiotic-resistant bacteria. Nowadays,
antibiotic resistant bacteria represent an important medical
problem. An increasing number of drug resistant-bacterial
infections are very difficult to treat (Go´rski et al. 2009).
Bacteriophages are an alternative to antibiotics. They can
be used as a useful tool against pathogenic bacteria. Special
properties of PEGylated bacteriophages such as long per-
sistence in the organism together with drug-targeting
bacteriophages may contribute to the development of
phage therapy.
Bacteriophages are viruses which can recognize and bind
specific bacterial receptors and create covalent bonds
between phage particles and gold surfaces. This method is
used for constructing biosensors by phage covalent immo-
bilization. Detection of E. coli K12 can be done by covalent
immobilization of T4 bacteriophages onto gold surfaces
using a self-assembled monolayer of dithiobis(succinimidyl
propionate) (DTSP) (Arya et al. 2011). E. coli is a natural
inhabitant of the intestinal tracts of humans and warm-
blooded animals. Although some pathogenic strains of
E. coli cause diarrhea, bloody feces, kidney failure, hemo-
lytic uremic syndrome and even death, it is a common food-
borne pathogen (Ho et al. 2004). Bacteriophage T4 can
recognize and bind to specific receptors on the E. coli host
using T4 tail spike proteins (Karam 1994; Kutter and Su-
lakvelidze 2005). A bioassay platform utilizing T4
bacteriophages via a specific receptor has been developed
for the detection of E. coli K12 bacteria.
Petrenko (2008) has pointed out the potential of bacte-
riophages in creation of bioselective materials and
eventually in constructing phage-derived analytical plat-
forms. Phages can be used as a recognition element in
biosensors by using physical adsorption to immobilize
phage on the sensor surface. Filamentous phages are most
commonly used in biosensor construction. This phages
characterized by simple composition. The major desired
characteristics of the biosensors are their sensitivity,
selectivity, robustness and prompt performance. Phage
layers bind biological agents with high affinity and speci-
ficity and generate detectable signals in analytical
platforms, for instance, it can be used for detection of
Bacillus anthracis spores and S. typhimurium cells (Petre-
nko 2008). Biosensors may solve the problem of detection
of many pathogenic and food borne bacteria or their when
their concentration is low (for standard detection methods)
but still harmful for the consumers’ health.
Conclusions
Nowadays medicine is still intensively searching for new
and imaginative solutions of difficult problems. These
problems are for example, new generations of anticancer
agents that would allow for replacement of traditional ones,
new types of biosensors that may help in easy detection of
still dangerous bacteria, or vaccine development since we
still face the threat of HIV and other difficult pathogens.
Phages offer solutions for many of those challenges. They
are a very useful tool in medicine and biotechnology,
showing encouraging results. Phage can be applied as
anticancer agents, novel platforms in vaccine design, or as
target carriers in drug discovery. They offer solutions for
modern cell imaging, biosensor construction or food
pathogen detection. Bacteriophage research is a dynami-
cally developing field with promising prospects for further
development of medicine and biotechnology.
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